Citations

Clear

151 citation(s) found for "Beltran, H".

Association Between Sleep Apnea Symptoms Subtypes and Obesity
Henríquez-Beltrán, Mario, Solomons, Daniel , Troncoso, María F., Martínez, Montserrat Sánchez, Jorquera, Jorge , Labarca, Gonzalo , Labarca, Gonzalo , Henríquez‐Beltrán, Mario , Troncoso, Maria Fernanda , Sanchez3, Montserrat

Mayo Clinic

Journal of Clinical Medicine | May 21, 2026 | Volume: 15 | Issue: 10 | Pages: 3969

10.3390/jcm15103969 | PMID 42194930 Get It

Background and Objectives: Obstructive sleep apnea (OSA) is a heterogeneous disease with diverse clinical presentations and high global prevalence. Obesity is a common comorbidity in OSA, but its relationship with symptom subtypes remains unclear. This study aimed to evaluate the association between OSA symptom subtypes and obesity in a clinical cohort. Methods: This observational study analyzed data from the Santiago Obstructive Sleep Apnea (SantOSA) prospective clinical cohort, including adults with OSA confirmed by home sleep apnea testing. Symptom subtypes were identified using latent class analysis. Associations between obesity and symptom subtypes were evaluated using multivariable regression models adjusted for age, sex, tobacco use, RDI, T90%, TST, hypertension, and diabetes. Statistical significance was set at p < 0.05. Results: A total of 1167 patients were included (943 men). Latent class analysis identified three symptom subtypes: non-sleepy, disturbed sleep, and excessive daytime sleepiness. Among obese patients, 30.7%, 50.0%, and 19.3% were classified into these subtypes, respectively. Obesity prevalence was 50.2%, and compared with non-obese OSA patients, obese patients showed a higher prevalence of severe OSA (46.1% vs. 26.9%), hypertension (54.4% vs. 34.9%), and diabetes (37.2% vs. 19.4%), as well as higher ESS scores and higher RDI and T90% values (all p < 0.01). In adjusted analyses, obesity remained independently associated with the excessive daytime sleepiness subtype after controlling for age, sex, tobacco use, RDI, T90%, TST, and comorbidities. Conclusions: Obesity is highly prevalent in OSA and is associated with specific symptom-defined phenotypes, particularly excessive daytime sleepiness and disturbed sleep. These findings support the relevance of considering symptom profiles alongside traditional severity metrics.
A prospective risk analysis for the clinical commissioning of a dose-driven continuous scanning proton therapy system
Herchko, Steven, Liang, Xiaoying, Beltran, Chris, Liang, Xiaoying, Shen, Jiajian , Furutani, Keith M.

Mayo Clinic

Frontiers in Oncology | May 20, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fonc.2026.1826522 | PMID 42245713 Get It

Introduction Proton dose driven continuous scanning (DDCS) is a form of proton pencil beam scanning (PBS) in which the beam may remain on during transitions between successive spots. Mayo Clinic Florida (MCF) is preparing to commission a synchrotron-based proton therapy system designed for DDCS, incorporating novel irradiation control features. Given the novelty and complexity of this system, a systematic risk-based analysis was performed to inform upcoming commissioning strategies. Methods A prospective risk analysis was conducted using the American Association of Physicists in Medicine (AAPM) Task Group 100 (TG 100) framework. A comprehensive process map of the DDCS irradiation control workflow was developed. Failure modes and effects analysis (FMEA) was performed to identify potential delivery system failure modes and to score each failure mode based on occurrence, severity, and lack of detectability. Targeted mitigation and commissioning strategies were then developed to address the highest-risk items. Results Twenty-nine delivery system failure modes were identified. The highest-risk failure modes were specific to DDCS operation. Targeted commissioning strategies were defined, including scan path measurement and modeling, validation of move and flap dose, dose monitor collection efficiency testing, spot position monitor performance evaluation, and verification of control system intervention behavior. Incorporation of these strategies into the commissioning plan reduced the mean RPN by more than 50%. Discussion This work provides a detailed description of the MCF proton DDCS irradiation control system and uses a TG 100 based approach for identifying system-specific risks. As new systems incorporate technologies for which limited guidance exists, institutions must perform their own risk analyses to determine appropriate quality management strategies.
Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management
Castillo, Jorge J. , Beltran, Brady E. , Florindez, Jorge A. , Chávez, Julio C. , Malpica, Luis, Malpica, Luis , Malpica Castillo, Luis E , Chavez, Julio C , Castillo, Jorge J

Mayo Clinic

American Journal of Hematology | May 15, 2026 | Volume: 101 | Issue: 8 | Pages: 1997-2006

10.1002/ajh.70373 | PMID 42138287 Get It

ABSTRACT Disease Overview Plasmablastic lymphoma (PBL) is a rare CD20‐negative aggressive lymphoma with poor prognosis when treated with standard treatment options. Although PBL is associated with HIV infection and other immunosuppressed states, it can also affect immunocompetent individuals. Diagnosis The diagnosis of PBL requires a high clinical suspicion and pathological confirmation. EBV‐encoded RNA (EBER) expression and MYC gene rearrangements are frequently detected in the malignant cells. The differential diagnosis includes EBV+ diffuse large B‐cell lymphoma (DLBCL), extracavitary primary effusion lymphoma, ALK+ DLBCL, and HHV8+ large B‐cell lymphoma, among others. Risk Stratification Age ≥ 60 years, advanced clinical stage, and high International Prognostic Index scores are associated with worse survival. Management Combination chemotherapy regimens, such as infusional EPOCH, are recommended. The addition of bortezomib or daratumumab might improve outcomes. B‐cell maturation antigen‐targeted therapies have shown early efficacy. The participation of patients with PBL in prospective clinical trials is warranted.
Surgical Versus Medical Management in Older Adults with Traumatic Brain Injury: A Systematic Review and Meta-analysis
Fuente, Andrea C. Beltran-De La , Ayala-Alban, Mael S. , Acosta, Sergio Morales , Carrión-Cuéllar, Astrid G. , Pérez, Olga N. Polania, Rathod, Rupesh G. , Lopez-Gonzales, Manuel E. , Barreto, Ana Karina La Madrid , Rangel-Castilla, Leonardo, Cueva-Cañola, Luis E. , Polania-Pérez, Olga N. , Rangel-Castilla, Leonardo

Mayo Clinic

No container title available | May 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9362369/v1 Get It

Abstract Background Traumatic brain injury (TBI) in older adults is associated with high mortality and poor functional outcomes. However, optimal management remains uncertain, as evidence comparing surgical and medical strategies is limited, heterogeneous, and extrapolated from younger populations. We conducted a systematic review and meta-analysis to compare outcomes between surgical and medical management in this population. Methods PubMed, Embase, and Web of Science were searched from database inception to December 8, 2025. Studies including adults aged ≥60 years with TBI comparing surgical versus medical management were included. The primary outcome was favorable neurological outcome, while secondary outcomes included hospital length of stay (LOS) and mortality. Pooled estimates were calculated as risk ratios (RR) and mean differences (MD) using random-effects models with restricted maximum likelihood and Hartung–Knapp adjustment. Results Sixteen cohort studies comprising 132,823 patients were included. Surgical management was not associated with improved favorable neurological outcomes at discharge, 3, 6, or 12 months. However, it was associated with longer LOS (MD = 6.35 days, 95% CI: 2.55 to 10.14; p < 0.01). No differences were observed in in-hospital, 30-day, 3-month, 12-month, or 24-month mortality. Notably, surgical management was associated with a reduction in 6-month mortality (RR = 0.68, 95% CI: 0.51–0.92; p = 0.02). Conclusions In older adults with TBI, surgical management was associated with reduced 6-month mortality and longer hospital LOS, but not with improved functional outcomes, highlighting a dissociation between survival and recovery. This dissociation has implications for clinical decision-making and patient and family counseling. Individualized decision-making that incorporates frailty, comorbidities, and potential reversibility of injury is essential, rather than relying solely on age. While this study represents the best available comparative evidence to date on surgical versus non-surgical management in older adults with TBI, findings should be interpreted with caution due to heterogeneity and low to very low certainty of the evidence. High-quality randomized controlled trials are needed to better define the role of surgery in this population.
Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102)
Chen, Yu‐Wei , Bobek, Olivia , Heller, G., Berg, S., Tan, Alan , Zhao, Shuang G. , Galsky, Matthew D. , Beltran, Himisha , McKay, Rana R. , Berg, Stephanie , Berg, Stephanie A , Zhao, Shuang G , Galsky, Matthew D , Rosenberg, Jonathan E , Beltran, Himisha , McKay, Rana R , Bobek, Olivia , Heller, Glenn , Chen, Yu-Wei

Mayo Clinic

JCO Oncology Advances | April 9, 2026 | Volume: 3 | Issue: 2 | Pages: No page available

10.1200/oa-25-00187 | PMID 42232816 Get It

Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
Tagawa, S, Sartor, O, Piulats, J M, Saad, F, Fizazi, K, Reid, A H, Beltran, H, Kramer, G, Eiber, M, Gupta, S, Gauna, D E Castellano, Hauke, R, Kim, H, Pang, S-T., Bouillaud, Emmanuel, Zhang, A., Sakharova, O, Morris, M J, Piulats, Josep M. , Saad, Fred , Fizazi, Karim , Reid, A H, Mahammedi, Hakim , Gupta, Shilpa , Gauna, D.E. Castellano, Hauke, Ralph J. , Kwak, Cheol Hun , Zhang, Alison Yan , Sakharova, Olga V., Morris, Michael J.

Mayo Clinic

Nuklearmedizin - NuclearMedicine | April 2, 2026 | Volume: 65 | Issue: 02 | Pages: 107-107

10.1055/s-0046-1818191 Get It

Physician perspectives on the implementability of a cardiovascular risk score for prostate cancer: A PRISM-guided evaluation.
Kruse-Diehr, Aaron, Koo, Phillip J. , Armstrong, Andrew J., Swami, Umang , Efstathiou, Eleni , Morgans, Alicia K., Alumkal, Joshi J. , Palapattu, Ganesh S. , Beltran, H., Roy, S., Moses, Kelvin A. , Satkunasivam, Raj, Klaassen, Z., Agarwal, Neeraj, Guha, Avirup, Armstrong, Andrew J. , Armstrong, Andrew J , Kunhiraman, Harikrishnan Hyma , Kruse‐Diehr, Aaron J. , Morgans, Alicia K. , Hahn, Andrew W. , Riaz, Irbaz Bin , Esdaille, Ashanda Rosetta Patrice , Harrison, Michael R. , Satkunasivam, Raj , Agarwal, Neeraj , Guha, Avirup

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 57-57

10.1200/jco.2026.44.7_suppl.57 Get It

57 Background: Cardiovascular disease (CVD) is the leading non-cancer cause of death among men with prostate cancer (PC), particularly during androgen-deprivation therapy. While CVD risk-prediction models are well established in the general population, barriers to integration within oncology workflows remain poorly defined. Guided by the PRISM and RE-AIM frameworks, this study evaluated multilevel determinants influencing adoption, feasibility, and sustainability of CVD risk-assessment tools in PC care. Methods: A national, cross-sectional survey of 45 physicians (medical oncology 49%, urology 38%, radiation oncology 13%) from 18 U.S. states was conducted. Respondents represented early- (27%), mid- (36%), and late-career (38%) clinicians across academic (87%) and community (13%) settings. Quantitative items mapped to PRISM/RE-AIM domains assessed adaptability, cost/resource feasibility, effectiveness, equity, and sustainability; open-ended responses explored contextual barriers and facilitators. Descriptive statistics summarized quantitative data. Results: Physicians reported moderate-to-high readiness to adopt a CVD risk-assessment tool, emphasizing workflow alignment and EHR integration over algorithmic complexity. Table 1 summarizes domain-specific findings. Ninety-three percent of respondents favored lab-independent models that minimize workflow disruption. Conclusions: Pre-implementation analysis highlighted that structural barriers, rather than algorithmic or statistical limitations, remain the primary obstacles to adopting CVD risk-assessment tools in prostate-cancer care. Physicians emphasized the need for EHR-integrated, non-laboratory-based, and time-efficient tools that align with routine oncology workflows and minimize cross-specialty friction. Addressing these practical and organizational determinants may be pivotal to achieving equitable, scalable, and sustainable cardio-oncology implementation across diverse practice settings. PRISM and RE-AIM constructs evaluation results. Construct Likely/Very Likely (%) Interpretation Perceived Effectiveness 87% Broad confidence in clinical utility Equity in Patient Reach 75% Strong perceived equity in reach Equity in Effectiveness 73% Expected to perform consistently across populations Adaptability to Workflow 71% High compatibility with existing clinic workflows Cost/Resource Feasibility 65% Feasible for resource-constrained settings Likelihood of Adoption 60% Moderate readiness for implementation Equity in Adoption 58% Equitable uptake possible despite resource differences Reach to Target Population 57% Moderate likelihood of reaching most patients Sustainability Over Time 51% Moderate long-term feasibility Consistency of Implementation 42% Need for standardized protocols
Trial design and objectives for prostate cancer: Recommendations from the Prostate Cancer Clinical Trials Working Group 4 (PCWG4).
Armstrong, Andrew J., Morris, Michael J., Antonarakis, Emmanuel S., Beltran, Himisha, Halabi, Susan, Herrmann, Ken, Hofman, Michael S., Hope, MD Thomas A., Liu, Glenn X., McKay, Rana R., Morgans, Alicia K., Stadler, Walter M., Sternberg, Cora N., Yu, Evan Y., Scher, Howard I., Investigators, PCWG4, Halabi, Susan , Armstrong, Andrew J. , Halabi, Susan , Armstrong, Andrew J , Morris, Michael J. , Antonarakis, Emmanuel S. , Bryce, Alan H. , Emmett, Louise , Hermann, Ken , Hofman, Michael S. , Lang, Joshua M. , Liu, Glenn , McKay, Rana R. , Morgans, Alicia K. , Paller, Channing J. , Stadler, Walter M. , Sternberg, Cora N , Szmulewitz, Russell Z , Yu, Evan Y , Scher, Howard I.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 162-162

10.1200/jco.2026.44.7_suppl.162 Get It

162 Background: Clinical trial conduct in advanced prostate cancer has changed dramatically with the continued development of new imaging approaches, molecular phenotypes and genetic subtypes, prognosis assessments, and effective therapies across a range of disease states. This created a need to redefine terminology and best practices for clinical trials. Methods: We convened PCWG4, an international expert committee of multidisciplinary working groups, between 2016 and 2025 to update and expand PCWG2-3 recommendations based on emerging evidence and clinical trial data in an innovative biomarker and imaging context to provide guidance for clinical trial design, eligibility, and endpoint assessments. Results: PCWG4 redefines terminology around disease states and prior therapies in a patient-centric context, considering imaging modalities, with a particular focus on PET-defined disease. New recommendations are provided for disease state terminology, defining eligibility criteria, imaging and non-imaging-based responses. We define delay/prevent endpoints including responses by pathology, ctDNA, circulating tumor cells, and PSA declines, and specify intervals for re-assessments including imaging, biomarker assessments, and patient reported outcomes. We propose new imaging-specific rPFS criteria including guidance with serial PSMA PET/CT imaging (Table). We provide recommendations in a biomarker-based context for the indication, reflective of patient benefit for specific interventions. We emphasize the need for development of validated PET imaging and molecular and phenotypic criteria as well as trial designs to appropriately risk stratify patients, predict and assess benefit, and measure post-treatment outcomes reliably in a trial framework. Conclusions: PCWG4 expands guidance on patient and tumor profiling, as well as therapy development, to include both androgen deprivation therapy sensitive and resistant settings, reflecting today’s more heterogeneous and diverse patient population to optimize outcomes. PCWG4-defined radiographic progression by imaging modality for patients with metastatic disease. Pretreatment Scan On-treatment Scan #1(≥week 8) On-treatment Scan #2 All Subsequent Scans Bone scintigraphy Comparator Comparator for subsequent scansPOD never called here POD:PCWG3 criteria (2+2 additional new lesions) POD:≤5 new lesions: PCWG3 criteria 2 new lesions confirmed≥6 new lesions CT/MRI Any measurable disease Comparator PCWG3/RECIST PCWG3/RECIST PCWG3/RECIST PSMA PET Bones, and lymph nodes and lung metastases (non-RECIST qualifying by + on PET only) Comparator POD:≤5 new lesions: 2 new lesions confirmed on a subsequent scan≥6 new lesions Same as prior Same as prior Liver and non-pulmonary viscera Comparator POD:Any single new lesion that represents disease Same as prior Same as prior
ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).
Kilari, Deepak, Ballman, K., Gelmann, Edward P. , Zarrabi, Kevin , Baghaie, Shiva, Sumey, Christopher , Nguyen, Paul, Montgomery, R Bruce, Berg, S., Tan, Alan W.C. , Jacene, H., Chen, Ronald C., Beltran, Himisha, Morris, Michael J., Galsky, Matthew D. , Rosenberg, Jonathan E., McKay, Rana R., Kilari, Deepak , Hillman, David W. , Bryce, Alan H. , Rose, Brent Shane , Tan, Alan, Jacene, Heather A. , Chen, Ronald C., Morris, Michael J. , Rosenberg, Jonathan E , McKay, Rana R.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps290 Get It

TPS290 Background: Landmark randomized trials established the survival benefit of adding D to ADT in mCSPC. Building on this foundation, subsequent trials (PEACE-1 and ARASENS) demonstrated further survival improvements when androgen receptor pathway inhibitors (ARPI) were added to the ADT + D backbone. However, the independent contribution of D within the triplet regimen remains unclear given lack of prospective evaluation. Additionally, tumor suppressor gene (TSG) alterations involving TP53, PTEN, and RB1 are frequently observed in PC and are associated with aggressive biology and poor outcomes, providing an opportunity to enhance prognostic accuracy and optimize selection of candidates for treatment intensification. We hypothesize that adding D to ADT plus A will improve survival compared to ADT + A in mCSPC and stratification by TSG status may identify different treatment effects across molecular subgroups. Methods: ASPIRE is an open-label, two-arm, randomized phase 3 study to assess the benefit of D added to ADT plus A for patients with mCSPC. Eligible patients include those with confirmed adenocarcinoma of the prostate with evidence of distant metastatic disease on conventional imaging and are appropriate to receive D. Patients with metachronous low-volume disease or PSMA-PET only disease are excluded. Candidates must have next-generation sequencing (NGS) results from a CLIA-certified tissue test available for TSG status stratification at registration. Eligible patients will receive ADT plus A (240 mg PO daily) +/- D for up to 6 cycles until progression of disease by PCWG3/RECIST version 1.1 criteria. Prior therapy with ADT (with or without ARPI) initiated within 120 days before registration is permitted. The primary endpoint is overall survival (OS). Secondary endpoints include OS by TSG status; radiographic progression-free survival (rPFS); time to castration resistance; symptomatic skeletal event–free survival; time to worsening of disease-related symptoms (NCCN-FACT FPSI-17); safety and tolerability (CTCAE v5.0); PSA90 response at 6 weeks and 6 months; time to PSA progression; and objective response rate in patients with measurable disease. The study will enroll 1200 patients and is currently actively accruing patients. Clinical trial information: NCT06931340 .
Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102).
Chen, Yu-Wei , Zhao, Shuang G. , Shah, Dhaval, Tan, Alan, Berg, S., Morris, Michael J., Galsky, Matthew D. , Rosenberg, Jonathan E., Beltran, Himisha, McKay, Rana R., Bobek, Olivia , Heller, Glenn , Zhao, Shuang G , Wulff, Elizabeth, Morris, Michael J. , Rosenberg, Jonathan E , McKay, Rana R.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps277 Get It

TPS277 Background: Recent advances in genomic sequencing have deepened our understanding of the molecular complexity of metastatic castration-resistant prostate cancer (mCRPC), revealing multiple actionable alterations that now inform biomarker-driven treatment strategies. Accordingly, germline and somatic tumor profiling is recommended for all patients with mCRPC. Beyond DNA aberrations, gene expression profiling can uncover additional therapeutic targets and pathway activations. The phase 2 PREDICT trial is leveraging both DNA and RNA alterations to guide rationally designed, biomarker-based therapeutic approaches for patients with mCRPC. Methods: This multi-center, multi-arm, biomarker-driven phase 2 umbrella trial is evaluating rationally selected therapies for patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint is objective response rate in patients with measurable disease, with secondary endpoints including radiographic progression-free survival, PSA response, time to first symptomatic skeletal event, overall survival, safety, and correlative biomarker analyses. Eligible patients must have progressive mCRPC of any histology, prior treatment with an androgen receptor pathway inhibitor (ARPI), and either prior or declined taxane chemotherapy, with both measurable and non-measurable disease permitted. Enrollment requires standard-of-care next-generation DNA sequencing from tissue or circulating tumor DNA performed in a CLIA-certified laboratory, and RNA-based allocation will use the CLIA-certified Caris MI Tumor Seek assay (whole exome and whole transcriptome sequencing) on tissue obtained within 12 months of study entry, with a real-time molecular tumor board reviewing results to confirm arm assignment. Patients with RB1 loss (DNA), an RB functional loss signature (RNA), or an NEPC signature (RNA) will receive the EZH1/2 inhibitor valemetostat; those with ≥2 of 3 tumor suppressor gene alterations (TP53, RB1, PTEN), FANC alterations (DNA), or SLFN11 overexpression (RNA) will receive cabazitaxel plus carboplatin; and those without study-defined alterations will receive physician’s choice of cabazitaxel, ARPI, or 177Lu-PSMA-617. The design permits incorporation of additional biomarker-defined arms, and up to 158 patients per arm (64 with measurable and 94 with non-measurable disease) will be accrued under a Simon two-stage minimax design, providing a one-sided type I error of 0.05 if the true response rate is 0.20 and 90% power if the response rate is 0.37 (Clinical trial information: NCT06632977). Clinical trial information: NCT06632977 .